Efficacy of Platinum-based Chemotherapy Plus Immune Checkpoint Inhibitors for EGFR/ALK/ROS1 Mutant Lung Cancer

Sponsor
Hunan Province Tumor Hospital
Study ID
NCT05284539
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The investigators want to evaluate the Efficay and Safety of Platinum-based Chemotherapy with or without immune checkpoint inhibitors for EGFR/ALK/ROS1 Positive NSCLC who Failed from First-Line Standard Treatment.

Key Dates

First listed
Mar 17, 2022
Start date
Apr 1, 2022
Status verified
Jun 2024
Primary completion
Sep 30, 2026
Completion
Oct 10, 2027

Study Design

Enrollment
760 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Arm A: EGFR mutant Group
    EGFR mutant Group.
  • Experimental: Arm B: ALK fusion Group
    ALK fusion Group.
  • Experimental: Cohort C: ROS1 fusion Group.
    ROS1 fusion Group.

Primary Outcome Measure

Progression-free survival (PFS) [ Time Frame: Time from first subject dose to study completion, or up to 36 month ]

Central Contacts

Related Studies